Charles River Laboratories International, Inc.
Key Metrics
- Previous Close
- $290.00
- 52-Week Range
- $144.26 – $299.32
- Market Cap
- $14.04B
- P/E (TTM)
- —
- EPS (TTM)
- -4.81
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 4.90
- PEG Ratio
- 0.12
- Return on Equity
- -7.52%
- Return on Assets
- 4.11%
- Gross Margin
- 34.59%
- Operating Margin
- 15.11%
- Profit Margin
- -5.96%
- Current Ratio
- 1.35
- Debt/Equity
- 1.05
- Total Debt
- $3.03B
- Free Cash Flow
- $468.86M
- Revenue Growth
- -2.70%
- Earnings Growth
- —
- Enterprise Value
- $16.74B
Market Snapshot
About
Charles River Laboratories International, Inc. provides early-stage contract research services to pharmaceutical, biotechnology, and medical device companies and government agencies. The company offers research models and services (laboratory animals, research model services), discovery and safety assessment (drug discovery, safety testing, pathology), and manufacturing solutions (biologics testing, sterility assurance, specialty services). Charles River serves biopharmaceutical clients requiring preclinical research services including toxicology studies, pathology, bioanalytical services, and specialized testing supporting drug development. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River has built one of the world's leading preclinical CRO platforms through organic growth and strategic acquisitions. The company benefits from essential services in drug development, long-standing client relationships, scientific expertise, global capabilities, and barriers to entry including specialized facilities and regulatory expertise. Charles River faces competitive CRO markets, customer spending patterns, pricing pressures, and cyclicality in pharmaceutical R&D investment. The company continues to invest in capabilities, geographic expansion, and strategic growth initiatives to support biopharmaceutical innovation globally.